Clinical efficacy and effectiveness of Sativex ®, a combined cannabinoid medicine, in multiple sclerosis-related spasticity

Expert Review of Neurotherapeutics

Volumn 12, Issue 4 SUPPL., 2012, Pages 3-8

  Oreja Guevara, Celia ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

clinical efficacy; multiple sclerosis; nabiximols; quality of life; Sativex ; spasticity

Indexed keywords

BACLOFEN; BENZODIAZEPINE; BOTULINUM TOXIN; CANNABIDIOL; CANNABIS; DRONABINOL; GABAPENTIN; NABIXIMOLS; TIZANIDINE;

CLINICAL EFFECTIVENESS; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL (TOPIC); DAILY LIFE ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; EVIDENCE BASED PRACTICE; FUNCTIONAL STATUS; HEALTH SURVEY; HUMAN; MONOTHERAPY; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PREVALENCE; QUALITY OF LIFE; SPAIN; SPASTICITY; TREATMENT DURATION; TREATMENT RESPONSE;

CANNABINOIDS; CLINICAL TRIALS AS TOPIC; HUMANS; MULTIPLE SCLEROSIS; MUSCLE SPASTICITY; PLANT EXTRACTS; QUALITY OF LIFE; SPAIN;

EID: 84860118395     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.12.11     Document Type: Conference Paper

References (26)

1. Stevenson VL. Rehabilitation in practice: spasticity management. Clin. Rehabil. 24, 293-304 (2010).
2. Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult. Scler. 10, 589-595 (2004). (Pubitemid 39207235)
3. Sosnoff JJ, Gappmaier E, Frame A, Motl RW. Influence of spasticity on mobility and balance in persons with multiple sclerosis. J. Neurol. Phys. Ther. 35, 129-132 (2011).
4. Shakespeare DT, Boggild M, Young C. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst. Rev. 2, CD001332 (2004).
5. Arroyo R, Vila C, Clissold S. Retrospective observational study of the management of multiple sclerosis patients with resistant spasticity in Spain: the '5E' study. Expert Rev. Pharmacoecon. Outcomes Res. 11, 205-213 (2011).
6. Oreja-Guevara C, González D, Vila C, de Sola S. Multiple sclerosis spasticity in Spain: the 6E patients' survey. Mult. Scler. 17(Suppl. 10), S80 (2011).
7. Farrar JT, Troxel AB, Stott C, Duncombe P, Jensen MP. Validity, reliability, and clinical importance of change in a 0-10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial. Clin. Ther. 30, 974-985 (2008). (Pubitemid 351799873)
8. Chong MS, Wolff K, Wise K, Tanton C, Winstock A, Silber E. Cannabis use in patients with multiple sclerosis. Mult. Scler. 12, 646-651 (2006). (Pubitemid 46940639)
9. Pérez J. Combined cannabinoid therapy via an oromucosal spray. Drugs Today 42, 495-501 (2006).
10. Ware MA, Adams H, Guy GW. The medicinal use of cannabis in the UK: results of a nationwide survey. Int. J. Clin. Pract. 59, 291-295 (2005). (Pubitemid 40352745)
11. Russo EB. Cannabinoids in the management of difficult to treat pain. Ther. Clin. Risk Manag. 4, 245-249 (2008).
12. Pertwee RG. Cannabinoid pharmacology: the first 66 years. Br. J. Pharmacol. 147, S163-S171 (2006). (Pubitemid 43077274)
13. Di Marzo V, Petrosino S. Endocannabinoids and the regulation of their levels in health and disease. Curr. Opin. Lipidol. 18, 129-140 (2007). (Pubitemid 46412082)
14. Pryce G, Baker D. Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors. Br. J. Pharmacol. 150, 19-25 (2007).
15. Stott CG, Wright S, Guy GW. A comparison of pharmacokinetic profiles of inhaled delta-9-tetrahydrocannabinol (THC) from smoked cannabis with Sativex® oromucosal spray in humans: implications for possible symptomatic treatment in multiple sclerosis. Eur. J. Neurol. 15(Suppl. 3), 365 (2008).
16. Collin C, Davies P, Mutiboko IK, Ratcliffe S; for the Sativex Spasticity in MS Study Group. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur. J. Neurol. 14, 290-296 (2007). (Pubitemid 46384865)
17. Collin C, Ehler E, Waberzinek G et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol. Res. 32, 451-459 (2010).
18. Novotna A, Mares J, Ratcliffe S et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur. J. Neurol. 18, 1122-1131 (2011).
19. Collin C, Serpell M, Potts R. Results of an open-label extension trial of Sativex (THC:CBD) in patients with multiple sclerosis and symptoms of spasticity. Mult. Scler. 13, S129 (2007).
20. Wade DT, Makela PM, House H, Bateman C, Robson P. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult. Scler. 12, 639-645 (2006). (Pubitemid 46940638)
21. Wade DT, Collin C, Stott C, Duncombe P. Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Mult. Scler. 16, 707-714 (2010).
22. Montalbán X, Sastre Garriga J, Vila C, Clissold SP. THC and CBD oromucosal spray (Sativex) in the management of spasticity associated with multiple sclerosis. Expert Rev. Neurother. 11, 627-637 (2011).
23. Notcutt W, Langford R, Davies P, Ratcliffe S, Potts R. A placebo-controlled, parallel-group, randomised withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who were receiving long term Sativex® (nabiximols). Mult. Scler. 18(2), 219-228 (2012).
24. Wade D, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult. Scler. 10, 434-441 (2004). (Pubitemid 39117341)
25. Montalbán X, Wright S. Trial period for new symptomatic treatments: lessons learnt from a Sativex in MS spasticity clinical trial. Mult. Scler. 15, S272 (2009).
26. House H, Bateman C, Wade DT. Long-term Sativex (THC:CBD) use in multiple sclerosis: benefits to daily life and functional activities. Mult. Scler. 13, S267 (2007).